Methods for Integration of Pharmacokinetic and Phenotypic Information in the Treatment of Infection with Human Immunodeficiency Virus
Open Access
- 1 February 2003
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (3) , 373-377
- https://doi.org/10.1086/345993
Abstract
Interest in monitoring antiretroviral drug concentrations in human immunodeficiency virus-infected patients has gained considerable momentum in recenKeywords
This publication has 11 references indexed in Scilit:
- Position Paper on Therapeutic Drug Monitoring of Antiretroviral AgentsAIDS Research and Human Retroviruses, 2002
- Simplifying Protease Inhibitor Therapy with Once-Daily Dosing of Saquinavir Soft-Gelatin Capsules/Ritonavir (1600/100 mg): HIVNAT 001.3 StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Pharmacokinetic Profile and Tolerability of Indinavir-Ritonavir Combinations in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2001
- Steady-State Pharmacokinetics of Twice-Daily Dosing of Saquinavir Plus Ritonavir in HIV-1–Infected IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- The Steady‐State Pharmacokinetics of Efavirenz and Nevirapine When Used in Combination in Human Immunodeficiency Virus Type 1–Infected PersonsThe Journal of Infectious Diseases, 2001
- A Retrospective, Cohort-Based Survey of Patients Using Twice-Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and EfficacyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week resultsAIDS, 2001
- LopinavirDrugs, 2000
- Pharmacodynamics of Human Immunodeficiency Virus Type 1 Protease InhibitorsClinical Infectious Diseases, 2000
- Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency VirusVirology, 1998